These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 23060300)

  • 21. Oncotype DX Breast Cancer recurrence score resists inter-assay reproducibility with RT
    Schildgen V; Warm M; Brockmann M; Schildgen O
    Sci Rep; 2019 Dec; 9(1):20266. PubMed ID: 31889145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Semi-quantitative immunohistochemical assay versus oncotype DX(®) qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study.
    Kraus JA; Dabbs DJ; Beriwal S; Bhargava R
    Mod Pathol; 2012 Jun; 25(6):869-76. PubMed ID: 22301704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is There a Role for Oncotype Dx Testing in Invasive Lobular Carcinoma?
    Conlon N; Ross DS; Howard J; Catalano JP; Dickler MN; Tan LK
    Breast J; 2015; 21(5):514-9. PubMed ID: 26271749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features.
    Geradts J; Bean SM; Bentley RC; Barry WT
    Cancer Invest; 2010 Nov; 28(9):969-77. PubMed ID: 20873988
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BreastPRS is a gene expression assay that stratifies intermediate-risk Oncotype DX patients into high- or low-risk for disease recurrence.
    D'Alfonso TM; van Laar RK; Vahdat LT; Hussain W; Flinchum R; Brown N; John LS; Shin SJ
    Breast Cancer Res Treat; 2013 Jun; 139(3):705-15. PubMed ID: 23774991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive Histologic Scoring to Maximize the Predictability of Pathology-generated Equation of Breast Cancer Oncotype DX Recurrence Score.
    Khoury T; Huang X; Chen X; Wang D; Liu S; Opyrchal M
    Appl Immunohistochem Mol Morphol; 2016; 24(10):703-711. PubMed ID: 26808126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data.
    Orucevic A; Bell JL; McNabb AP; Heidel RE
    Breast Cancer Res Treat; 2017 May; 163(1):51-61. PubMed ID: 28243897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation between HER2 determined by fluorescence in situ hybridization and reverse transcription-polymerase chain reaction of the oncotype DX test.
    Dvorak L; Dolan M; Fink J; Varghese L; Henriksen J; Gulbahce HE
    Appl Immunohistochem Mol Morphol; 2013 May; 21(3):196-9. PubMed ID: 22914611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Breast cancer tumor heterogeneity has only little impact on the estimation of the Oncotype DX® recurrence score using Magee Equations and Magee Decision Algorithm™.
    Remoué A; Conan-Charlet V; Deiana L; Tyulyandina A; Marcorelles P; Schick U; Uguen A
    Hum Pathol; 2021 Feb; 108():51-59. PubMed ID: 33245987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Routine Use of Oncotype DX Recurrence Score Testing in Node-Positive Hormone Receptor-Positive HER2-Negative Breast Cancer: The Time Has Come.
    Mittendorf EA; King TA
    Ann Surg Oncol; 2019 May; 26(5):1173-1175. PubMed ID: 30798446
    [No Abstract]   [Full Text] [Related]  

  • 31. Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score.
    Turner BM; Skinner KA; Tang P; Jackson MC; Soukiazian N; Shayne M; Huston A; Ling M; Hicks DG
    Mod Pathol; 2015 Jul; 28(7):921-31. PubMed ID: 25932962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical roundtable monograph: a multidisciplinary approach to the use of oncotype DX in clinical practice.
    Gradishar WJ; Hansen NM; Susnik B
    Clin Adv Hematol Oncol; 2009 Apr; 7(4):1-7. PubMed ID: 19536946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is the Oncotype DX assay necessary in strongly estrogen receptor-positive breast cancers?
    Lee JJ; Shen J
    Am Surg; 2011 Oct; 77(10):1364-7. PubMed ID: 22127090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Initial experience with the Oncotype DX assay in decision-making for adjuvant therapy of early oestrogen receptor-positive breast cancer in Hong Kong.
    Cheung PS; Tong AC; Leung RC; Kwan WH; Yau TC
    Hong Kong Med J; 2014 Oct; 20(5):401-6. PubMed ID: 24948666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncotype DX test on unequivocally HER2-positive cases: potential for harm.
    Bhargava R; Dabbs DJ
    J Clin Oncol; 2012 Feb; 30(5):570-1. PubMed ID: 22231038
    [No Abstract]   [Full Text] [Related]  

  • 36. Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation.
    Biroschak JR; Schwartz GF; Palazzo JP; Toll AD; Brill KL; Jaslow RJ; Lee SY
    Breast J; 2013; 19(3):269-75. PubMed ID: 23614365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes.
    Cobleigh MA; Tabesh B; Bitterman P; Baker J; Cronin M; Liu ML; Borchik R; Mosquera JM; Walker MG; Shak S
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8623-31. PubMed ID: 16361546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Routine histopathologic characteristics can predict oncotype DX(TM) recurrence score in subsets of breast cancer patients.
    Mattes MD; Mann JM; Ashamalla H; Tejwani A
    Cancer Invest; 2013 Nov; 31(9):604-6. PubMed ID: 24164299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A simple immunohistochemical bio-profile incorporating Bcl2 curbs those cases of invasive breast carcinoma for which an Oncotype Dx characterization is needed.
    Ceccarelli C; De Leo A; Chieco P; Zamagni C; Zamagni A; Rubino D; Taffurelli M; Santini D
    PLoS One; 2019; 14(6):e0217937. PubMed ID: 31158261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset.
    Harowicz MR; Robinson TJ; Dinan MA; Saha A; Marks JR; Marcom PK; Mazurowski MA
    Breast Cancer Res Treat; 2017 Feb; 162(1):1-10. PubMed ID: 28064383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.